-
公开(公告)号:US11584757B2
公开(公告)日:2023-02-21
申请号:US16802654
申请日:2020-02-27
申请人: Celgene CAR LLC
发明人: Matthew David Alexander , Claudio Chuaqui , John Malona , Joseph John McDonald , Yike Ni , Deqiang Niu , Russell C. Petter , Juswinder Singh , Chittari Pabba
IPC分类号: A61K31/551 , A61P25/00 , A61P31/00 , C07D495/14 , A61P37/00 , A61P35/00
摘要: The present invention provides compounds, compositions thereof, and methods of using the same.
-
公开(公告)号:US11572371B2
公开(公告)日:2023-02-07
申请号:US16647837
申请日:2018-09-14
发明人: Lei Fan , Kexin Xu , Ke Chen , Fei Wang , Xiaoquan Wu , Tongchuan Luo , Shaohua Zhang , Xinghai Li , Yuanwei Chen
IPC分类号: C07D495/14 , A61P35/00
摘要: Disclosed is a BRD4 inhibitor as shown in formula I, belonging to the field of compound drugs. The compound provided has a good inhibitory effect on prostate cancer cell proliferation, and can be used for preparing a drug combatting tumors, autoimmune or inflammatory diseases and viral infection, and in particular an anti-prostate cancer drug.
-
公开(公告)号:US11557738B2
公开(公告)日:2023-01-17
申请号:US16786483
申请日:2020-02-10
发明人: Tyler Fleetham , Peter Wolohan
IPC分类号: H01L51/00 , C07F7/08 , C07D487/14 , C07D493/14 , C07D493/22 , C07D495/14 , C07F5/02 , H01L51/50
摘要: A compound of Formula I: wherein: X1-X8 are each independently C or N, wherein two adjacent X1-X8 are carbon-fused to a structure of Formula II: X9-X12 are each independently C or N; A1, A2, and A3 are each independently selected from the group consisting of O, S, Se, N, NR, CR, CRR′, SiR, SiRR′, GeR, and GeRR′, with at least one of A1 and A2 being N or NR; each occurrence of is independently a single bond or a double bond, wherein one occurrence of is a single bond and one occurrence of is a double bond; each of RA, RB, and Rc independently represents zero, mono, or up to a maximum allowed substitution to its associated ring; each of occurrence R, R′, RA, RB, and RC is independently a hydrogen or a substituent selected from the group consisting of Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, boryl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof, with at least one of R, R′, RA, RB, and RC comprising a group of Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, or Formula IX: each occurrence of Y1, Y2, and Y3 is independently absent, O, S, Se, NR, CRR′, SiRR′, or GeRR′; each occurrence of Ar1, and Ar2 is independently an optionally substituted aryl group or an optionally substituted heteroaryl group, wherein Ar1 and Ar2 are optionally joined or fused together to form a ring; each occurrence of X13-X20 is independently C or N, with the proviso that at least one of X13-X20 is N; each occurrence of A4 is selected from the group consisting of O, S, Se, NR, CRR′, SiRR′, and GeRR′; each occurrence of RX independently represents zero, mono, or up to a maximum allowed substitution to its associated ring; each occurrence of RX is independently a hydrogen or a substituent selected from the group consisting of deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, boryl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof; each occurrence of RY is independently a hydrogen or a substituent selected from the group consisting of Formula III, Formula IV, Formula V, Formula VI, Formula IX, deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, boryl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof; the maximum number of N atoms that are connected to each other within a ring is two; and any two substituents are optionally joined or fused together to form a ring.
-
公开(公告)号:US20220380387A1
公开(公告)日:2022-12-01
申请号:US17764778
申请日:2021-01-22
IPC分类号: C07F5/02 , C07D493/04 , C07C211/54 , C07C15/20 , C07D209/82 , C07D405/10 , C07D491/048 , C07D409/10 , C07D405/14 , C07F7/08 , C07D403/14 , C07D409/14 , C07D487/04 , C07D471/04 , C07D409/04 , C07D401/14 , C07D251/24 , C07D403/04 , C07D403/10 , C07D333/76 , C07D307/91 , C07D235/08 , C07F9/53 , C07C13/72 , C07D519/00 , C07D487/14 , C07D495/04 , C07C15/38 , C07D413/10 , C07D491/147 , C07D413/14 , C07D495/14 , C07D401/04 , C07D487/16 , C07D241/46 , H01L51/00 , H01L51/50
摘要: An organic electroluminescence device includes an anode, a cathode, and an emitting layer disposed between the anode and the cathode. The emitting layer comprises a delayed fluorescent compound M2 having at least one deuterium atom and a compound M3 having at least one deuterium atom. A singlet energy S1(M2) of the compound M2 and a singlet energy S1(M3) of the compound M3 satisfy the relationship S1(M3)>S1(M2).
-
公开(公告)号:US20220363640A1
公开(公告)日:2022-11-17
申请号:US17208964
申请日:2021-03-22
发明人: Guangyi WANG , Leonid BEIGELMAN , Anh TRUONG , Carmela NAPOLITANO , Daniele ANDREOTTI , Haiying HE , Karin Ann STEIN
IPC分类号: C07D213/40 , C07D409/04 , C07D495/14 , C07D401/04 , C07D413/04 , C07D417/04 , C07D239/34 , C07D471/04 , C07D213/65 , C07D401/12 , C07D491/048 , C07D233/64 , C07D409/14 , C07D417/06 , C07D413/12 , C07D413/06 , C07D401/06 , C07D405/12 , C07D417/12 , C07D207/273 , C07D491/052 , A61K31/4436 , A61K31/4418 , A61K31/4178 , A61K31/4439 , A61K31/4365 , A61K31/422 , A61K31/4196 , A61K31/427 , A61K31/505 , A61K31/437 , A61K45/06 , A61K31/4355 , A61K31/444 , A61K31/4709
摘要: Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).
-
公开(公告)号:US20220348593A1
公开(公告)日:2022-11-03
申请号:US17535124
申请日:2021-11-24
申请人: Genentech, Inc.
发明人: Jennafer Dotson , Robert Andrew Heald , Timothy Heffron , Graham Elgin Jones , Sussie Lerche Krintel , Neville James McLean , Chudi Ndubaku , Alan G. Olivero , Laurent Salphati , Lan Wang , BinQing Wei
IPC分类号: C07D498/22 , C07D471/14 , C07D491/14 , C07D495/14 , C07D487/14 , C07D498/14 , A61K31/5377 , A61K31/5383 , A61K31/5386 , A61K39/395 , C07D491/147 , C07D498/20 , C07K16/22
摘要: Tricyclic PI3k inhibitor compounds of Formula I with anti-cancer activity, anti-inflammatory activity, or immunoregulatory properties, and more specifically with PI3 kinase modulating or inhibitory activity are described. Methods are described for using the tricyclic PI3K inhibitor compounds of Formula I for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions. Formula I compounds include stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof. The dashed lines indicate an optional double bond, and at least one dashed line is a double bond. The substituents are as described.
-
公开(公告)号:US11447464B2
公开(公告)日:2022-09-20
申请号:US16330254
申请日:2017-09-11
申请人: Merck Patent GmbH
IPC分类号: C07D401/04 , C07D401/10 , C07D401/14 , C07D403/04 , C07D403/10 , C07D403/14 , C07D405/14 , C07D471/04 , C07D487/04 , C07D491/147 , C07D495/04 , C07D495/14 , C07D498/14 , C07D513/04 , C07D513/14 , H01L51/00 , C07D471/14 , C09K11/06 , C07D498/04 , H01L51/50
摘要: The invention relates to spirobifluorene derivatives which are substituted with electron transport groups, in particular for use in electronic devices. The invention further relates to a method for producing the compounds according to the invention, and to electronic devices comprising the same.
-
公开(公告)号:US20220235068A1
公开(公告)日:2022-07-28
申请号:US17595869
申请日:2020-05-29
发明人: Gang Li , Lun Lu , Zhibo Zhang , Lihong Hu , Charles Z. Ding , Shuhui Chen
IPC分类号: C07D495/14 , C07D519/00
摘要: A new class of tetracyclic compounds acting as Cdc7 inhibitors; specifically disclosed are a compound represented by formula (I), isomers thereof, or pharmaceutically acceptable salts thereof.
-
公开(公告)号:US20220223794A1
公开(公告)日:2022-07-14
申请号:US17191837
申请日:2021-03-04
申请人: Wuhan Tianma Micro-Electronics Co., Ltd. , Wuhan Tianma Microelectronics Co., Ltd.Shanghai Branch
发明人: Wei GAO , Wenpeng DAI , Lei ZHANG , Quan RAN , Lu ZHAI , Lilian KUANG
IPC分类号: H01L51/00 , C07D491/048 , C09K11/06 , C07D491/147 , C07D495/14
摘要: A heterocyclic compound containing heteroatom substituted fluorene is provided in the present disclosure. The heterocyclic compound includes a structure: Y1 is selected from O or S; X1, X2, X3, X4, X5, X6, X7, and X8 are independently selected from CRa or N; X9, X10, X11, X12, X13, X14, X15, X16, X17, X18, X19, X20, X21, X22, X23, and X24 are independently selected from CR1 or N; Ra is independently selected from hydrogen, deuterium, tritium, halogen, nitrile, cyano, nitro, hydroxyl, carbonyl, ester, carboxyl, imide, amide, C1-C20 alkoxy, C1-C20 alkyl, C3-C20 cycloalkyl, C2-C20 alkenyl, C3-C20 cycloalkenyl, silyl, boron, phosphine oxide, phosphine, sulfonyl, amine, C6-C30 aryl, C3-C30 heteroaryl, or a ring structure; Y2, and Y3 are independently selected from O, S or NR2; Ar1 and Ar2 are independently selected from aryl or heteroaryl; and R1 and R2 are independently selected from hydrogen, deuterium, C1-C20 alkyl, C6-C30 aryl, or C3-C30 heteroaryl.
-
公开(公告)号:US11365200B2
公开(公告)日:2022-06-21
申请号:US16496376
申请日:2018-03-22
申请人: TAIPEI MEDICAL UNIVERSITY , NATIONAL RESEARCH INSTITUTE OF CHINESE MEDICINE, MINISTRY OF HEALTH AND WELFARE , ACADEMIA SINICA , BUDDHIST TZU CHI MEDICAL FOUNDATION
发明人: Heng Lin , Ming-jaw Don , Ching-feng Cheng , Jing-jy Cheng , Wen-shan Li , Hui-chen Ku , Hsiao-fen Li , Hsi-hsien Chen , W J Huang
IPC分类号: C07D493/04 , C07D495/04 , A61K31/366 , A61K31/381 , A61P3/10 , A61P3/04 , C07D491/153 , A23L33/10 , C07D491/052 , C07D495/14
摘要: The invention relates to compounds for treating and/or preventing obesity and obesity-related disorders. Particularly, the invention provides chromanone derivatives used as ATF3 inducer and for treating and/or preventing obesity and obesity-related disorders such as heart disease, hypertension, hyperlipidemia and diabetes.
-
-
-
-
-
-
-
-
-